TRUMBULL, Conn.--(BUSINESS WIRE)--A National Cancer Institute (NCI) investigator’s endorsement of inaccurate high-risk HPV test to refer women to cervical cancer tests, despite the weak evidence of its value, is “unfortunate and inappropriate.” Sin Hang Lee, MD, president of HiFi DNA Tech, in a letter published in Infectious Agents and Cancer entitled “HPV test is a virology test, not for predicting cancer” (http://www.infectagentscancer.com/content/4/1/7/comments#342631), challenged the official Commentary of Dr. Philip E. Castle, principle investigator of the NCI human papillomavirus (HPV) project.
